Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: A crossover, observer-masked, three-centre study

British Journal of Ophthalmology

Volumn 91, Issue 6, 2007, Pages 757-760

  Konstas, Anastasios G P ^a   Hollo G ^b   Irkec, M ^d   Tsironi, S ^c   Durukan, I ^d   Goldenfeld, M ^e   Melamed, S ^e  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c G Papanikolaou Hospital   (Greece)

^d HACETTEPE UNIVERSITY   (Turkey)

^e Sam Romberg Glaucoma Centre   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST;

AGED; APPLICATION SITE REACTION; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EXFOLIATIVE GLAUCOMA; EYE COLOR; EYE PAIN; FOLLOW UP; FOREIGN BODY REACTION; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; LID DERMATITIS; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PERIOCULAR PIGMENTATION; PIGMENTATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; CLOPROSTENOL; CROSS-OVER STUDIES; EXFOLIATION SYNDROME; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; SINGLE-BLIND METHOD;

EID: 34249782847     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.106690     Document Type: Article

References (22)

1. Ritch R, Schlötzer-Schrehardt U, Konstas AGP. Why is glaucoma associated with exfoliation syndrome? Prog Retin Eye Res 2003;22:253-75.
2. Konstas AGP, Tsironi S, Ritch R. Update on the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma. Compr Ophthalmol Update 2006;7:131-41.
3. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001;45:265-315.
4. Konstas AGP, Stewart WC, Stroman GA. Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open-angle glaucoma. Ophthalmic Surg Lasers 1997;28:111-17.
5. Konstas AGP, Holló G, Astakhov Y, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004;122:29-33.
6. Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye 2004;18:893-9.
7. Konstas AGP, Kozobolis VP, Tersis I, et al. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 2003;17:41-6.
8. Konstas AGP, Maltezos A, Bufidis T, et al. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000;14:73-7.
9. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology, 1997;104, 137-42.
10. Konstas AGP, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology, (in press).
11. Konstas AGP, Tsironi S, Kozobolis VP. Medical therapy of exfoliative glaucoma. In:ln: Konstas AGP, Hollo G, eds. From exfoliation syndrome to exfoliative glaucoma. EGS book, (in press).
12. Konstas AGP, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-6.
13. Law SK, Song BJ, Fang E, et al. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 2005;112:2123-30.
14. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
15. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
16. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45:S353-60.
17. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21.
18. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (Lumigan) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003;110:2362-8.
19. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002;19:231-48.
20. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
21. Konstas AGP, Matziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:111-17.
22. Konstas AG, Matziris DA, Gate EA, et al. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:975-9.